A Phase 3 interventional study of ALXN2220 in Transthyretin Amyloid Cardiomyopathy (ATTR-CM), sponsored by Alexion Pharmaceuticals, Inc.. Not yet recruiting at 195 sites in 27 countries. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will receive ALXN2220 administered IV q4w for a minimum of 12 months and up to 24 months or until participant has access to commercially available ALXN2220 for ATTR-CM, whichever occurs first.
Drug: ALXN2220
To be administered as an IV infusion
Also known as: Cliramitug, NI006
Percentage of participants with TEAEs
To evaluate the long-term safety and tolerability of ALXN2220 in participants with ATTR-CM
Time frame: Up to 24 months
Total occurrence of ACM and CV clinical events
To evaluate the long-term efficacy of ALXN2220 on ACM and CV clinical events
Time frame: Up to 24 months
Total occurrence of CV clinical events
To evaluate the long-term efficacy of ALXN2220 on CV clinical events
Time frame: Up to 24 months
Time to ACM
To evaluate the long-term efficacy of ALXN2220 on ACM
Time frame: Up to 24 months
Time to first CV clinical event or ACM
To evaluate the long-term efficacy of ALXN2220 on first CV clinical event or ACM
Time frame: Up to 24 months
Time to CVM
To evaluate the long-term efficacy of ALXN2220 on CVM
Time frame: Up to 24 months
Change from baseline in KCCQ-OS by visit
To assess the long-term efficacy of ALXN2220 on symptoms, functionality, and health-related QoL.
Time frame: Up to 24 months
Change from baseline in 6MWT by visit
To assess the long-term efficacy of ALXN2220 on functional capacity
Time frame: Up to 24 months
ADA incidence, response categories, and titer
To assess long-term immunogenicity to ALXN2220
Time frame: Up to 24 months
NAb incidence and response categories
To assess long-term immunogenicity to ALXN2220
Time frame: Up to 24 months
Showing the first 100 of 195 sites across 27 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
No publications or documents are linked to this record.
Start is estimated for Nov 2027; primary completion for Jul 2030, 31 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cliramitug
Alexion Pharmaceuticals, Inc. →